Anti-idiotype responses abrogate anti-CD4-induced tolerance to a tumor-specific antigen and promote systemic tumor immunity

Cancer Immunology, Immunotherapy

Volumn 53, Issue 11, 2004, Pages 987-994

  Kennedy, Ronald C ^a   Shearer, Michael H ^a   Lowe, Devin B ^a   Jumper, Cynthia A ^b   Chiriva Internati, Maurizio ^a   Bright, Robert K ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER SCHOOL OF MEDICINE   (United States)

Author keywords

Anti idiotypes; Cancer vaccination; CD4+ T cells; Monoclonal antibody; Tumor antigen

Indexed keywords

CANCER VACCINE; CD4 ANTIBODY; CD4 ANTIGEN; IDIOTYPIC ANTIBODY; MONOCLONAL ANTIBODY; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIBODY RESPONSE; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; CANCER THERAPY; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; FLOW CYTOMETRY; IMMUNIZATION; IMMUNOLOGICAL TOLERANCE; LUNG METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY; VACCINATION;

ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; ANTIGENS, CD4; ANTIGENS, NEOPLASM; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE, TRANSFORMED; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; IMMUNE TOLERANCE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN IDIOTYPES; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; NEOPLASMS; RATS; T-LYMPHOCYTES; TIME FACTORS;

EID: 5644226215     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-004-0547-3     Document Type: Article

References (34)

1. Benton PA, Kennedy RC (1997) DNA vaccine strategies for the treatment of cancer. Curr Top Microbiol Immunol 226:1
2. Greenberg PD (1991) Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv Immunol 49:281
3. Melief CJ, Kast WM (1995) T cell immunotherapy of tumors by adoptive transfer of cytotoxic T lymphocytes and vaccination with minimal essential epitopes. Immunol Rev 145:167
4. Pardoll DM (2000) Therapeutic vaccination for cancer. Clin Immunol 10:544
5. Pardoll DM, Topalian SL (1998) The role of CD4+ T cell responses in antitumor immunity. Curr Opin Immunol 10:588
6. Kennedy RC, Shearer MH (2003) A role for antibodies in tumor immunity. Int Rev Immunol 22:1
7. Dalgleish AG (2001) Current problems in the development of specific immunotherapeutic approaches to cancer. J Clin Pathol 54:675
8. Ioannides C, Whiteside T (1993) T cell recognition of human tumors: implication for molecular immunotherapy of cancer. Clin Immunol Immunopathol 66:91
9. Sulitzeanu D (1993) Immunosuppressive factors in human cancer. Adv Cancer Res 60:247
10. Shimizu J, Yamazaki S, Sakaguchi S (1999) Induction of tumor immunity by removing CD25+ CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol 163:5211
11. van Elsas A, Sutmuller RPM, Hurwitz AA, Ziskin J, Villasenor J, Medema J-P, Overwijk WW, Restifo NP, Melief CJM, Offringa R, Allison JP (2001) Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockage in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy. J Exp Med 194:481
12. Demanet C, Brissinck J, De Jonge J, Thielemans K (1996) Bispecific antibody mediated immunotherapy of the BCL1 lymphoma: increased efficacy with multiple injections and CD28-induced costimulation. Blood 87:4390
13. McLaughlin JP, Schlom J, Kantor JA, Greiner JW (1996) Improved immunotherapy of a recombinant carcinoembryonic antigen vaccinia vaccine when given in combination with interleukin-2. Cancer Res 56:2361
14. Pulaski BA, Clements VK, Pipeling MR, Ostrand-Rosenberg S (2000) Immunotherapy with vaccines combining MHC class II/CD80+ tumor cells with interleukin-12 reduces established metastatic disease and stimulated immune effectors and monokine induced by interferon gamma. Cancer Immunol Immunother 49:34
15. Shimizu K, Fields RC, Redman BG, Giedlin M, Mule JJ (2000) Potentiation of immunologic responsiveness to dendritic cell based tumor vaccines by recombinant interleukin-2. Cancer J Sci Am 6:S67
16. Sondel PM, Hank JA (1997) Combination therapy with interleukin-2 and antitumor monoclonal antibodies. Cancer J Sci Am 1:S121
17. Tatsumi T, Takehara T, Kanto T, Miyagi T, Kuzushita N, Sugimoto Y, Jinushi M, Kasahara A, Sasaki Y, Hori M, Hayashi N (2001) Administration of interleukin-12 enhances the therapeutic efficacy of dendritic cell based tumor vaccines in mouse hepatocellular carcinoma. Cancer Res 61:7563
18. Wen XY, Mandelbaum S, Li ZH, Hitt M, Graham FL, Hawley TS Hawley RG, Stewart AK (2001) Tricistronic viral vectors co-expressing interleukin-12 and CD80 (B7-1) for immunotherapy of cancer: preclinical studies in myeloma. Cancer Gene Ther 8:361
19. Phillips TM (1988) High performance immunoaffinity chromatographic detection of immunoregulatory anti-idiotypic antibodies in cancer patients receiving immunotherapy. Clin Chem 34:1689
20. Goronzy J, Wehand CM, Fathman CG (1986) Long-term humoral unresponiveness in vivo induced by treatment with monoclonal antibody against L3T4. J Exp Med 164:911
21. Watts AM, Shearer MH, Pass HI, Kennedy RC (1997) Development of an experimental murine pulmonary metastasis model incorporating a viral encoded tumor specific antigen. J Virol Meth 69:93
22. Bright RK, Shearer MH, Kennedy RC (1994) Immunization of BALB/c mice with recombinant SV40 large tumor antigen induces antibody-dependent cell-mediated cytotoxicity (ADCC) against SV40 transformed cells: an antibody based mechanism for tumor immunity. J Immunol 153:2064
23. Kennedy RC, Shearer MH, Watts AM, Bright RK (2003) CD4+ T lymphocytes play a critical role in antibody production and tumor immunity against simian virus 40 large tumor antigen. Cancer Res 63:1040
24. Shearer MH, Bright RK, Kennedy RC (1993) Comparison of the humoral immune responses and tumor immunity in mice immunized with recombinant SV40 large tumor antigen and a monoclonal anti-idiotype. Cancer Res. 53:5734
25. Watts AM, Shearer MH, Pass HI, Kennedy RC (1999) Comparison of SV40 large tumor antigen recombinant protein and DNA immunization in the induction of protective immunity from experimental pulmonary metastasis in a murine model. Cancer Immunol Immunother 47:343
26. Benjamin RJ, Cobbold SP, Clark MR, Waldmann H (1986) Tolerance to rat monoclonal antibodies: implications for serotherapy. J Exp Med 163:1539
27. Kit S, Kurimura T, Dubbs DR (1969) Transplantable mouse tumor line induced by injection of SV40 transformed mouse kidney cells. Int J Cancer 4:384
28. Shearer MH, Chanh TC, Dalgleish AG, Kennedy RC (2000) Idiotype cascades associated with the CD4-HIV glycoprotein interaction: immunization with anti-idiotypic antibodies induces anti-anti-idiotypic responses with anti-CD4 specificity and in vitro neutralizing activity. AIDS Res Hum Retrovir uses 16:77
29. Lanford RE (1988) Expression of simian virus 40 T antigen in insect cells using a baculovirus expression system. Virology 167:72
30. Watts AM, Kennedy RC (1998) Quantitation of tumor foci in an experimental murine tumor model using computer assisted video imaging. Anal Biochem 256:217
31. Schick MR, Kennedy RC (1989) Methods for production and characterization of anti-idiotypic antibody reagents. Meth Enzymol 178:36
32. Attanasio R, Allan JS, Anderson SA, Chanh TC, Kennedy RC (1991) Anti-idiotypic antibodies responses to monoclonal anti-CD4 preparations in nonhuman primate species. J Immunol 146:507
33. Attanasio R, Dilley D, Buck D, Maino VC, Kanda P, Kennedy RC (1991) Structural characterization of a cross-reactive idiotype shared by monoclonal antibodies specific for the CD4 molecule. J Biol Chem 266:14611
34. Kennedy RC, Dreesman GR (1983) Common idiotypic determinant associated with human antibodies to hepatitis B surface antigen. J Immunol 130:385